1333-P: Diabetes Complications in Metropolitan vs. Nonmetropolitan Cities of India—Three-Year Follow-up Results of LANDMARC Trial

Abstract

Macrovascular and microvascular complications were evaluated in participants from metropolitan versus non-metropolitan cities during the three years of LANDMARC, a nationwide prospective observational study (CTRI/2017/05/008452). LANDMARC included participants with type 2 diabetes (T2D) who were on ≥2 antihyperglycemic medications. Of the total 6222 participants, 2375 and 3847 were from metropolitan and non-metropolitan cities, respectively. Age, T2D duration, and baseline A1C were similar across groups (Table). At the end of three-years, microvascular complications were significantly higher in participants from non-metropolitan than metropolitan cities (13.13% vs. 4.89%; p<0.0001). Neuropathy was the most common microvascular complication in both metropolitan and non-metropolitan cities. Among macrovascular complications, heart failure (p=0.0160) was reported more in non-metropolitan than metropolitan cities (Table). The LANDMARC data demonstrates that T2D participants from Indian non-metropolitan cities may have higher complications, particularly microvascular, and may need to be better understood through future studies. The LANDMARC results elicit a pattern of disease progression among participants with T2D. Disclosure S.Kalra: Speaker's Bureau; Abbott, Bayer Inc., Novo Nordisk, Sanofi. A.Sugumaran: Employee; Sanofi. A.Satpathy: Employee; Sanofi. A.Gadekar: Employee; Sanofi. S.K.Menon: Employee; Sanofi. R.Neogi: Employee; Sanofi. D.Chodankar: Employee; Sanofi. C.Trivedi: None. S.Wangnoo: None. A.H.Zargar: None. N.Rais: Advisory Panel; Bayer Consumer Care AG, Board Member; Abbott, Biocon. A.K.Das: n/a. S.R.Joshi: Advisory Panel; Biocon, Zydus Cadila, Torrent Pharmaceuticals Ltd, Franco India, Consultant; Glenmark Pharmaceuticals, Twin Health, Speaker's Bureau; Abbott Nutrition, Sanofi, Abbott, Novo Nordisk, Lupin Pharmaceuticals, Inc. A.Mithal: Advisory Panel; Eris Lifesciences Ltd., Consultant; Glenmark Pharmaceuticals, Lupin Pharmaceuticals, Inc., USV Private Limited, Research Support; Sanofi, Speaker's Bureau; Novo Nordisk, Boehringer-Ingelheim, AstraZeneca, Sun Pharmaceutical Industries Ltd., Novartis. K.Kumar: None. A.Unnikrishnan: Speaker's Bureau; Sanofi, AstraZeneca, Boehringer-Ingelheim, Intas Pharmaceuticals Ltd. H.Thacker: None. B.Sethi: None. S.Chowdhury: None. Funding Sanofi India